NeuroMetrix Inc (NURO) - Total Assets
Based on the latest financial reports, NeuroMetrix Inc (NURO) holds total assets worth $15.32 Million USD as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
NeuroMetrix Inc - Total Assets Trend (2002–2024)
This chart illustrates how NeuroMetrix Inc's total assets have evolved over time, based on quarterly financial data. Also see NeuroMetrix Inc stock valuation for the company's overall valuation and market capitalisation.
NeuroMetrix Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
NeuroMetrix Inc's total assets of $15.32 Million consist of 98.0% current assets and 2.0% non-current assets. Review total liabilities of NeuroMetrix Inc to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 9.3% |
| Accounts Receivable | $192.92K | 1.3% |
| Inventory | $1.35 Million | 8.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2002–2024)
This chart illustrates how NeuroMetrix Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See NeuroMetrix Inc stock quote for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: NeuroMetrix Inc's current assets represent 98.0% of total assets in 2024, an increase from 66.9% in 2002.
- Cash Position: Cash and equivalents constituted 9.3% of total assets in 2024, down from 38.3% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2002.
- Asset Diversification: The largest asset category is inventory at 8.8% of total assets.
NeuroMetrix Inc Competitors by Total Assets
Key competitors of NeuroMetrix Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Demant A/S
CO:DEMANT
|
Denmark | Dkr39.07 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.89 Billion |
|
4DMEDICAL Ltd
AU:4DX
|
Australia | AU$139.55 Million |
|
INKON Life Technology Co Ltd
SHE:300143
|
China | CN¥4.17 Billion |
|
SS Innovations International Inc. Common Stock
NASDAQ:SSII
|
USA | $96.98 Million |
|
LENSAR Inc
NASDAQ:LNSR
|
USA | $69.56 Million |
|
Lumos Diagnostics Holdings Ltd
AU:LDX
|
Australia | AU$21.12 Million |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
NeuroMetrix Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.83 | 10.91 | 3.06 |
| Quick Ratio | 13.50 | 10.11 | 2.57 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $14.00 Million | $18.30 Million | $4.98 Million |
NeuroMetrix Inc - Advanced Valuation Insights
This section examines the relationship between NeuroMetrix Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.66 |
| Latest Market Cap to Assets Ratio | 0.62 |
| Asset Growth Rate (YoY) | -28.5% |
| Total Assets | $15.32 Million |
| Market Capitalization | $9.43 Million USD |
Valuation Analysis
Below Book Valuation: The market values NeuroMetrix Inc's assets below their book value (0.62x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: NeuroMetrix Inc's assets decreased by 28.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for NeuroMetrix Inc (2002–2024)
The table below shows the annual total assets of NeuroMetrix Inc from 2002 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $15.32 Million | -28.47% |
| 2023-12-31 | $21.42 Million | -13.15% |
| 2022-12-31 | $24.67 Million | -0.88% |
| 2021-12-31 | $24.89 Million | +211.31% |
| 2020-12-31 | $7.99 Million | +15.97% |
| 2019-12-31 | $6.89 Million | -43.09% |
| 2018-12-31 | $12.11 Million | +26.19% |
| 2017-12-31 | $9.60 Million | +15.88% |
| 2016-12-31 | $8.28 Million | -48.34% |
| 2015-12-31 | $16.03 Million | +40.63% |
| 2014-12-31 | $11.40 Million | +5.61% |
| 2013-12-31 | $10.80 Million | -0.74% |
| 2012-12-31 | $10.88 Million | -23.51% |
| 2011-12-31 | $14.22 Million | -38.35% |
| 2010-12-31 | $23.07 Million | -43.14% |
| 2009-12-31 | $40.57 Million | +29.28% |
| 2008-12-31 | $31.38 Million | -44.34% |
| 2007-12-31 | $56.37 Million | +1.20% |
| 2006-12-31 | $55.71 Million | +29.86% |
| 2005-12-31 | $42.90 Million | +13.03% |
| 2004-12-31 | $37.95 Million | +425.82% |
| 2003-12-31 | $7.22 Million | +2.34% |
| 2002-12-31 | $7.05 Million | -- |
About NeuroMetrix Inc
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing and sale of medical devices. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; and Quell, a wearable device for symptomatic relief and management of chronic pain. The company offers its products to managed endoc… Read more